PMID- 23299929
OWN - NLM
STAT- MEDLINE
DCOM- 20130618
LR  - 20191210
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 143
DP  - 2013
TI  - The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor 
      genotyping on the outcome of patients receiving HLA-matched sibling donor 
      hematopoietic stem cell transplantation for myeloid malignancies.
PG  - w13717
LID - 10.4414/smw.2013.13717 [doi]
AB  - BACKGROUND: The alloreactivity of natural killer cell and certain subsets of T 
      lymphocyte are regulated by the interaction between killer immunoglobulin-like 
      receptors (KIRs) of donor cells and human leukocyte antigen (HLA)-class I 
      molecules on target cells. The interaction has been shown to influence the 
      outcome of allogeneic haematopoietic stem cell transplantation (HSCT). Homozygous 
      C1 or C2 and heterozygous C1/C2 were divided by HLA-Cw typing and they influenced 
      the outcome of HSCT. OBJECTIVE: The purpose of the study was to analyse the 
      impact of interaction between recipient HLA-Cw and donor KIR on outcome. METHODS: 
      The genotypes of recipient HLA-Cw ligands and donor KIRs were correlated with the 
      clinical outcomes of 52 patients who received HLA-matched, sibling donor HSCT for 
      myeloid malignancies. RESULTS: The incidence of chronic graft versus host disease 
      (GVHD) was significantly lower in C1 or C2 homozygotes than in C1/C2 
      heterozygotes (p = 0.000). Higher overall survival (OS) and disease-free survival 
      (DFS) rates were observed in C1 or C2 homozygotes than in C1/C2 heterozygotes 
      (OS, 81% +/- 8% vs 54% +/- 10%, p = 0.034; DFS, 81% +/- 8% vs 54% +/- 10%, p = 0.024). A 
      lower incidence of chronic GVHD and higher OS and DFS were observed in the 
      HLA-KIR mismatched group (chronic GVHD, p = 0.007; OS, 84% +/- 7% vs 47% +/- 13%, p = 
      0.003; DFS, 84% +/- 7% vs 47% +/- 13%, p = 0.002). CONCLUSION: The interaction 
      between recipient HLA ligand and donor KIR had a significant impact on the 
      outcome of patients receiving matched sibling HSCT. C1/C2 heterozygotes or 
      HLA-KIR matched patients may benefit from additional intensified therapy with 
      better outcome.
FAU - Wang, Hua
AU  - Wang H
AD  - Department of Haematology, Yantai Yu Hunag Ding Hospital, Yantai, China. 
      huagnaw@yahoo.com.cn
FAU - He, Yi
AU  - He Y
FAU - Zhai, Wen-jing
AU  - Zhai WJ
FAU - Wang, Mei
AU  - Wang M
FAU - Zhou, Zheng
AU  - Zhou Z
FAU - Zhao, Ying-xin
AU  - Zhao YX
FAU - Feng, Si-zhou
AU  - Feng SZ
FAU - Han, Ming-zhe
AU  - Han MZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130108
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
RN  - 0 (HLA-C Antigens)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Disease-Free Survival
MH  - Female
MH  - Genotype
MH  - Graft vs Host Disease/epidemiology/*immunology/mortality
MH  - HLA-C Antigens/genetics/*immunology
MH  - *Hematopoietic Stem Cell Transplantation/mortality
MH  - Heterozygote
MH  - Histocompatibility Testing
MH  - Homozygote
MH  - Humans
MH  - Leukemia, Myeloid/immunology/mortality/*surgery
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Receptors, KIR/genetics/*immunology
MH  - Recurrence
MH  - *Siblings
MH  - Transplantation Conditioning
MH  - Transplantation, Homologous
MH  - Young Adult
EDAT- 2013/01/10 06:00
MHDA- 2013/06/19 06:00
CRDT- 2013/01/10 06:00
PHST- 2013/01/10 06:00 [entrez]
PHST- 2013/01/10 06:00 [pubmed]
PHST- 2013/06/19 06:00 [medline]
AID - smw-13717 [pii]
AID - 10.4414/smw.2013.13717 [doi]
PST - epublish
SO  - Swiss Med Wkly. 2013 Jan 8;143:w13717. doi: 10.4414/smw.2013.13717. eCollection 
      2013.